Aurobindo Pharma has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Celecoxib Capsules, 50 mg, 100 mg, 200 mg, and 400 mg. This product is expected to be launched in Q4 FY15-16. The approved ANDA is bioequivalent and therapeutically equivalent to the reference listed drug product (RLD) Celebrex Capsules, 50 mg, 100 mg, 200 mg, and 400 mg, of GD Searle, LLC.
Celecoxib Capsules is used in the treatment of pain and inflammation of osteoarthritis, rheumatoid arthritis, Juvenile Rheumatoid Arthritis (2 years and older) ankylosing spondylitis, acute pain in adults, primary dysmenorrhea. The approved product has an estimated market size of US$ 976 million for the twelve months ending November 2015 according to IMS.
This is the 61st ANDA (including 11 tentative approvals) to be approved out of Unit VII formulation facility in Hyderabad, India for manufacturing Oral Non-Antibiotic products. the company now has a total of 235 ANDA approvals (203 Final approvals including 10 from Aurolife Pharma LLC and 32 Tentative approvals) from USFDA.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1847.30 |
| Dr. Reddys Lab | 1293.25 |
| Cipla | 1347.70 |
| Zydus Lifesciences | 938.90 |
| Lupin | 2377.90 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: